Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity

Annals of Pharmacotherapy

Volumn 28, Issue 9, 1994, Pages 1063-1072

  Seifert, Charles F ^a   Nesser, Mary Ellen ^b   Thompson, Dennis F ^c  

^a RAPID CITY REGIONAL HOSPITAL   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; RAZOXANE;

CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; HEART MITOCHONDRION; HEART PROTECTION; HUMAN; LIPID PEROXIDATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMAL; COMPARATIVE STUDY; DOGS; DOXORUBICIN; DRUG SYNERGISM; HUMAN; MYOCARDIAL DISEASES; RANDOMIZED CONTROLLED TRIALS; RATS; RAZOXANE; SWINE; SWINE, MINIATURE;

EID: 0028108109     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/106002809402800912     Document Type: Review

References (63)

1. Young RC Ozols RF Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139–53.
2. Von Hoff DD Layard MW Basa P Davis HL Von Hoff AL Rozencweig M., Risk factors for doxorubicin-induced heart failure. Ann Intern Med 1979; 91: 710–7.
3. Bristow MR Sageman WS Scott RH Billingham ME Bowden RE Kernoff RS, Acute and chronic cardiovascular effects of doxorubicin in the dog: The cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980; 2: 487–515.
4. Gottlieb JA LeFrak EA O'Bryan RM Burgess MA. Fatal adriamycin cardiomyopathy: Prevention by dose limitation. Proc Am Assoc Cancer Res 1973; 14: 88.
5. Billingham ME Mason JW Bristow MR Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–72.
6. Minow RA Benjamin RS Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy—an overview with determination of risk factors. Cancer Chemother Rep 1975; 6: 195–201.
7. Legha SS Benjamin RS Mackay B Ewer M Wallace S Valdivieso M., Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9.
8. Merrill J Greco FA Zimbler H Brereton HD Lamberg JD Pomeroy TC. Adriamycin and radiation: Synergistic cardiotoxicity. Ann Intern Med 1975; 82: 122–3.
9. Lambertenghi-Deliliers G Zanon PL Pozzoli EF. Myocardial injury induced by a single dose of adriamycin: An electron microscope study. Tumori 1976; 62: 517–28.
10. Arena E Biondo F D'Alessandro N. DNA, RNA and protein synthesis in the heart, liver, and brain of mice treated with daunomycin or adriamycin. Int Res Commun Sys Med Sci 1974; 2: 1053.
11. Zahringer J Hofling B Raum W Kandolph R. Effect of adriamycin on the polyribosome and messenger-RNA content of rat heart muscle. Biochem Biophys Acta 1980; 608: 315–23.
12. Unverferth BJ Magorien RD Balcerzak SP Leier CV Unverferth DV. Early changes in human myocardial nuclei after doxorubicin. Cancer 1983; 52: 215–21.
13. Ito H Miller SC Billingham ME Akimoto H Torti SV Wade R., Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A 1990; 87: 4275–9.
14. Olson HM Young DM Prieur DJ LeRoy AF Reagan RL. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol 1974; 3: 439–54.
15. Boucek RJ Olson RD Brenner DE Ogunbunmi EM Inui M Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J Biol Chem 1987; 262: 15851–6.
16. Kim DH Landry AB Lee YS Katz AM. Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 1989; 21: 433–6.
17. Olson RD Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 1990; 4: 3076–86.
18. Bachmann E Zbinden G. Effect of doxorubicin and rubidazone on respiratory function and Ca transport in rat heart mitochondria. Toxicol Lett 1979; 3: 29–34.
19. Jensen RA. Doxorubicin cardiotoxicity: Contractile changes after long-term treatment in the rat. J Pharmacol Exp Ther 1986; 236: 197–203.
20. Mushlin PS Olson RD. Anthracycline cardiotoxicity: New insights. Ration Drug Ther 1988; 22: 1–8.
21. Doroshow JH Locker GY Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 1980; 65: 128–35.
22. Keizer HG Pinedo HM Schuurhuis GJ Joenje H. Doxorubicin (Adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990; 47: 219–31.
23. Unverferth DV Fertel RH Balcerzak SP Magorien RD O'Dorisio MS. N-Acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP. Semin Oncol 1983; 10 (suppl 1): 49–52.
24. Olson RD MacDonald JS VanBoxtel CJ Boerth RC Harbison RD Slonim AE, Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J Pharmacol Exp Ther 1980; 215: 450–4.
25. Griffith OW Meister A. Glutathione: Interorgan translocation, turnover, and metabolism. Proc Natl Acad Sci U S A 1979; 76: 5606–10.
26. Powell SR McCay PB. Inhibition of doxorubicin-initiated membrane damage by N-acetylcysteine: Possible mediation by a thiol-dependent, cytosolic inhibitor of lipid peroxidation. Toxicol Appl Pharmacol 1988; 96: 175–84.
27. Locker G Doroshow J Myers C. Glutathione peroxidase: Its role in adriamycin cardiotoxicity. Proc Am Assoc Cancer Res 1977; 18: 87.
28. Del Tacca M Danesi R Ducci M Bernadini C Romanini A. Might adriamycinol contribute to Adriamycin-induced cardiotoxicity? Pharmacol Res Commun 1985; 17: 1073–84.
29. Peters JH Gordon DR Kashiwase D Acton EM. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmacol 1981; 7: 65–69.
30. Olson RD Mushlin PS Brenner DE Fleischer S Cusack BJ Chang BK, Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 1988; 85: 3585–9.
31. Fu LX Waagstein F Hjalmarson A. A new insight into Adriamycin-induced cardiotoxicity. Int J Cardiol 1990; 29: 15–20.
32. Bristow MR Kantrowitz NE Harrison WD Minobe WA Sageman WS Billingham ME. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 1983; 5: 913–9.
33. Mason JW Bristow MR Billingham ME Daniels JR. Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978; 62: 857–64.
34. Dey HM Kassamali H. Radionuclide evaluation of doxorubicin cardiotoxicity: The need for cautious interpretation. Clin Nucl Med 1988; 13: 565–8.
35. Ewer MS Ali MK Mackay B Wallace S Valdivieso M Legha SS, A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984; 2: 112–7.
36. Miller LF Rumack BH. Clinical safety of high oral doses of acetylcysteine. Semin Oncol 1983; 10: 76–85.
37. Johnston RE Hawkins HC Weikel JH. The toxicity of N-acetylcysteine in laboratory animals. Semin Oncol 1983; 10: 17–24.
38. Ziment I. Acetylcysteine: A drug that is much more than a mucokinetic. Biomed Pharmacother 1988; 42: 513–20.
39. Myers C Bonow R Palmeri S Jenkins J Corden B Locker G., A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10 (suppl 1): 53–55.
40. Alderton PM Gross J Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992; 52: 194–201.
41. Agen C Bernardini N Danesi R Della Torre P Costa M Del Tacca M. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemother Pharmacol 1992; 30: 95–99.
42. Herman EH Ferrans VJ. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 1983; 49: 69–77.
43. Perkins WE Schroeder RL Carrano RA Imondi AR. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br J Cancer 1982; 46: 662–7.
44. Herman EH Ferrans VJ. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds. Cancer Treat Rev 1987; 14: 225–9.
45. Herman EH Ferrans VJ Van Vleet JF. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res 1985; 45: 276–81.
46. Herman EH Ferrans VJ Young RSK Hamlin RL. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 1988; 48: 6918–25.
47. Villani F Galimberti M Monti E Cova D Lanza E Rozza-Dionigi A., Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol Appl Pharmacol 1990; 102: 292–9.
48. Speyer JL Green MD Kramer E Rey M Sanger J Ward C., Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745–52.
49. Speyer JL Green MD Zeleniuch-Jacquotte A Wernz JC Rey M Sanger J., ICRF-187 permits longer treatment with doxorubicin in women with breast cancer (published erratum appears in J Clin Oncol 1992;10:867). J Clin Oncol 1992; 10: 117–127.
50. Speyer JL Green MD Sanger J Zeleniuch-Jacquotte A Kramer E Rey M., A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 1990; 17: 161–3.
51. Williams GA Johnson JR Burke G. FDA oncology drugs advisory committee review of Zinecard (dexrazoxane, ADR-529, ICRF-187). Rockville, MD: Center for Drug Evaluation and Research, US Food and Drug Administration, 1992: 1–13.
52. Vile GF Winterbourn CC. dl-N,N′-dicarboxamidomethyl-N,N-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187): Inhibition of Fe(III) reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin. Cancer Res 1990; 50: 2307–10.
53. Myers CE Chabner BA. Anthracyclines. In: Myers CE Chabner BA, eds. Cancer chemotherapy: Principles and practice. Philadelphia: J B Lippincott, 1990: 356–81.
54. Thomas C Vile GF Winterbourn CC. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem Pharmacol 1993; 45: 1967–72.
55. Sobol MM Amiet RG Green MD. In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxopiperazine-1-yl)propane] onto an existing ferric-anthracycline complex. Mol Pharmacol 1992; 41: 8–17.
56. Alderton P Gross J Green MD. Role of (+/-)-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Cancer Res 1990; 50: 5136–42.
57. Hochster H Liebes L Wadler S Oratz R Wernz JC Meyers M., Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 1992; 84: 1725–30.
58. Baldwin JR Phillips BA Overmyer SK Hatfield NZ Narang PK. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. Cancer Chemother Pharmacol 1992; 30: 433–8.
59. Vogel CL Gorowski E Davila E Eisenberger M Kosinski J Agarwal RP, Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest New Drugs 1987; 5: 187–198.
60. Wadler S Green MD Muggia FM. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line. Cancer Res 1986; 46: 1176–81.
61. Wadler S Green MD Basch R Muggia FM. Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)−1,2,-bis(3–5-dioxopiperazinyl-1-yl)propane (ICRF 187), on murine sarcoma S180 in vitro. Biochem Pharmacol 1987; 36: 1495–501.
62. Curran CF Narang PK Reynolds RD. Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat Rev 1991; 18: 241–52.
63. Walsh C Blum RH Oratz R Goldenberg A Downey A Speyer JL. Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor. J Cancer Res Clin Oncol 1992; 118: 61–6.